Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cell Cycle

• Publication date

  2005-07-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.4.9.2038PMID 16103753
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers

  2005cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.

  2005cited by this paper
• Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer

  2005cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005cited by this paper
• Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

  2005cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005cited by this paper
• Evidence for two distinct binding sites for tau on microtubules.

  2004cited by this paper
• Mechanisms of Taxol resistance related to microtubules

  2003cited by this paper
• Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.

  2003cited by this paper
• Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

  2003cited by this paper
• Repeat motifs of tau bind to the insides of microtubules in the absence of taxol

  2003cited by this paper
• MAP2 and tau bind longitudinally along the outer ridges of microtubule protofilaments

  2002cited by this paper
• Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.

  1999cited by this paper
• DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.

  1999cited by this paper
• Taxol suppresses dynamics of individual microtubules in living human tumor cells.

  1999cited by this paper
• The microtubule-associated protein tau cross-links to two distinct sites on each alpha and beta tubulin monomer via separate domains.

  1998cited by this paper
• Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

  1997cited by this paper
• Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau.

  1992cited by this paper
• Taxol: Mechanisms of Action and Resistance a

  1986cited by this paper

• Therapeutic Contribution of Tau-Binding Thiazoloflavonoid Hybrid Derivatives Against Glioblastoma Using Pharmacological Approach in 3D Spheroids

  2024cites this paper
• Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease

  2024cites this paper
• Alzheimer's disease and related tauopathies: disorders of disrupted neuronal identity.

  2023cites this paper
• Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma

  2022cites this paper
• CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes

  2022cites this paper
• RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage

  2022cites this paper
• Identifying the genes impacted by cell proliferation in proteomics and transcriptomics studies

  2022cites this paper
• Tau Stabilizes Chromatin Compaction

  2021cites this paper
• Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer

  2020cites this paper
• Tau: At the Interface Between Neurodegeneration and Cancer?

  2020cites this paper
• Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

  2019cites this paper
• CMAR_A_215427 7391..7404

  2019cites this paper
• Tau regulates the microtubule-dependent migration of glioblastoma cells via the Rho-ROCK signaling pathway

  2019cites this paper
• Basic principles of drug delivery systems - the case of paclitaxel.

  2019cites this paper
• Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT

  2019cites this paper
• The challenge of drug resistance in cancer treatment: a current overview

  2018cites this paper
• PRP4K IS A NOVEL HER2-REGULATED MODIFIER OF ANOIKIS AND TAXANE RESISTANCE

  2018cites this paper
• Tau in Tauopathies That Leads to Cognitive Disorders and in Cancer

  2018cites this paper
• Tau-dependent suppression of adult neurogenesis in the stressed hippocampus

  2017cites this paper
• Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion

  2017cites this paper
• Brain Metastasis Prediction by Transcriptomic Profiling in Triple‐Negative Breast Cancer

  2017cites this paper
• Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy

  2017cites this paper
• Chrysoula Dioli

  2016cites this paper
• miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).

  2016cites this paper
• Microtubule‐Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy

  2016cites this paper
• Expression, phosphorylation, localization, and microtubule binding of tau in colorectal cell lines

  2016cites this paper
• Three-Dimensional Collagen Type I Matrix Up-Regulates Nuclear Isoforms of the Microtubule Associated Protein Tau Implicated in Resistance to Paclitaxel Therapy in Ovarian Carcinoma

  2015cites this paper
• Human tau expression reduces adult neurogenesis in a mouse model of tauopathy.

  2015cites this paper
• articleThe estrogen receptor influences microtubule-associated protein tau ( MAPT ) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells

  2015influential citation
• Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

  2015cites this paper
• Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy

  2015cites this paper
• Predictive and Prognostic Value of the TauProtein in Breast Cancer.

  2015cites this paper
• Altered adult neurogenesis in a mouse model of human tauopathy

  2015cites this paper
• End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability

  2014cites this paper
• Topoisomerase II Alpha and Microtubule-associated Protein-tau as a Predictive Marker in Axillary Lymph Node Positive Breast Cancer

  2014cites this paper
• Collapsin response mediator protein 2 is involved in regulating breast cancer progression

  2014cites this paper
• Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer

  2014cites this paper
• Relationship Between Gastric Cancer Tau Protein Expression and Paclitaxel Sensitivity

  2013cites this paper
• MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers

  2013cites this paper
• Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy

  2013cites this paper
• Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression

  2013cites this paper
• The application of Tau protein testing to gastric cancer patients treated with paclitaxel

  2013cites this paper
• New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer

  2013cites this paper
• Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

  2013cites this paper
• Tubulin: an example of targeted chemotherapy.

  2013cites this paper
• Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy

  2013cites this paper
• The Role of the Rho GEF Arhgef2 in RAS Tumorigenesis

  2013cites this paper
• Marqueurs pronostiques et prédictifs des cancers du sein précoces

  2012cites this paper
• PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy

  2012cites this paper
• Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells.

  2012cites this paper
• Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity.

  2012cites this paper
• New insights into tau-microtubules interaction revealed by isothermal titration calorimetry.

  2012cites this paper
• Investigation into taxane resistant breast cancer

  2011cites this paper
• Taxanes and Epothilones in Cancer Treatment

  2011cites this paper
• Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells

  2010cites this paper
• Genes that modulate the sensitivity for anti-microtubule drug-mediated chemotherapy.

  2010cites this paper
• Discovery ression and Silencing of the Microtubule-Associated Ther tein Tau in Breast Cancer Cells

  2010cites this paper
• [Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules].

  2010cites this paper
• Relationships between genetic polymorphisms and transcriptional profiles for outcome prediction in anticancer agent treatment.

  2010cites this paper
• Tubulin-independent tau in Alzheimer's disease and cancer: implications for disease pathogenesis and treatment.

  2010cites this paper
• Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis

  2010cites this paper
• Molecular Cancer apeutics apeutic Discovery ression and Silencing of the Microtubule-Associated Ther tein Tau in Breast Cancer Cells

  2010cites this paper
• A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

  2010cites this paper
• Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells

  2010cites this paper
• Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.

  2010cites this paper
• Equivalency of RT-PCR and immunohistochemistry: fact or factoid

  2009cites this paper
• Molecular mode of action and mechanism of resistance of the microtubule-stabilizing drug Sagopilone

  2009cites this paper
• Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer

  2009cites this paper
• Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome

  2009cites this paper
• Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

  2009cites this paper
• Microtubule‐associated protein tau in human prostate cancer cells: Isoforms, phosphorylation, and interactions

  2009influential citation
• CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.

  2008cites this paper
• Multigene predictors in early-stage breast cancer: moving in or moving out?

  2008cites this paper
• Taxanes, microtubules and chemoresistant breast cancer.

  2008cites this paper
• Commercialized multigene predictors of clinical outcome for breast cancer.

  2008cites this paper
• Chapter 49 – Natural and Acquired Resistance to Cancer Therapies

  2008cites this paper
• Markers predicting clinical benefit in breast cancer from microtubule-targeting agents.

  2007cites this paper
• ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells.

  2007cites this paper
• Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

  2007cites this paper
• Microtubule-Stabilizing Agent: Halichondrin B Analog (E7389)

  2007cites this paper
• Gene Expression Profiling and Clinical Outcome in Breast Cancer

  2006cites this paper
• Cancer Biomarkers—An Invitation to the Table

  2006cites this paper
• EGF Induces Cell Motility and Multi-Drug Resistance Gene Expression in Breast Cancer Cells

  2006cites this paper
• Open Access Research Article

  year unknowncites this paper